106362-32-7|肽T|Peptide T|-范德生物科技公司

肽T

NMR下载 COA and HPLC MSDS下载
names：
Peptide T
CAS号：
106362-32-7
MDL Number：
MF(分子式)： C35H55N9O16 MW(分子量)： 857.86
EINECS: Reaxys Number:
Pubchem ID:73352 Brand:BIOFOUNT

Peptide T(肽T,106362-32-7)又称为N-（N-（N（2）-（N-（N-（N-（ND-丙氨酰基L-丝氨酰基）-L-苏氨酰基）-L-苏氨酰基）L-苏氨酰基）-L-天冬酰胺基）-L-酪氨酸）L-苏氨酸。Peptide T与HIV包膜蛋白gp120共享序列同源性。可能的作用机制是 gp120 对 CD4 受体的竞争性抑制以及与血管肠肽受体的结合和抑制细胞因子作用.Peptide T 可能在艾滋病治疗中用作抗病毒药。五肽核心序列TTNYT由肽T中的氨基酸4-8组成，是附着至CD4受体所需的HIV包膜序列。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000698-5mg	5mg	>97%hc	¥ 2936.00	¥ 2936.00		Backorder	- +	¥ 0.00
YZM000698-1mg	1mg	>97%hc	¥ 675.00	¥ 675.00		1-3天	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	肽T(106362-32-7);HIV肽T;肽T;肽T，HIV;H-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-OH; L-丙氨酰-L-丝氨酰-L-苏氨酸-L-苏氨酸-L-苏氨酸-L-天冬酰胺-L-酪氨酰-L-苏氨酸; （2S，3R）-2-[[（2S）-2-[[（2S）-4-氨基-2-[[（2S，3R）-2-[[（2S，3R）-2-[[ （2S，3R）-2-[[（（2S）-2-[[（2S）-2-氨基丙酰基]氨基] -3-羟基丙酰基]氨基] -3-羟基丁酰基]氨基] -3-羟基丁酰基]氨基]- 3-羟基丁酰基]氨基] -4-氧丁酰基]氨基] -3-（4-羟基苯基）丙酰基]氨基] -3-羟基丁酸；HIV肽T; 肽T; 肽T，HIV;
英文别名	Peptide T(106362-32-7);HIV Peptide T;Peptide T;Peptide T, HIV; H-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-OH; L-alanyl-L-seryl-L-threonyl-L-threonyl-L-threonyl-L-asparagyl-L-tyrosyl-L-threonine; (2S,3R)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoic acid; HIV Peptide T; Peptide T; Peptide T, HIV;
CAS号	106362-32-7
SMILES	CC(C(C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C(C)O)C(=O)O)NC(=O)
Inchi	1S/C35H55N9O16/c1-13(36)28(52)40-22(12-45)31(55)41-25(15(3)47)33(57)43-26(16(4)48)34(58)42-24(14(2)46)32(56)39-21(11-23(37)51)29(53)38-20(10-18-6-8-19(50)9-7-18)30(54)44-27(17(5)49)35(59)60/h6-9,13-17,20-22,24-27,45-50H,10-12,36H2,1-5H3,(H2,37,51)(H,38,53)(H,39,56)(H,40,52)(H,41,55)(H,42,58)(H,43,57)(H,44,54)(H,59,60)/t13-,14+,15+,16+,17+,20-,21-,22-,24-,25-,26-,27-/m0/s1
InchiKey	IWHCAJPPWOMXNW-LYKMMFCUSA-N
分子式 Formula	C35H55N9O16
分子量 Molecular Weight	857.86
闪点 FP	860.7±34.3°摄氏度
熔点 Melting point	No data available
沸点 Boiling point	1499.5±65.0°C在760 mmHg
Polarizability极化度
密度 Density	1.4±0.1克/厘米3
蒸汽压 Vapor Pressure	25°C时为0.0±0.3 mmHg
溶解度Solubility
性状	Solid
储藏条件 Storage conditions	存放在阴凉干燥处

肽T(Peptide T,106362-32-7)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags：肽T试剂,肽T杂质,肽T中间体,肽T密度,肽T旋光度,肽T溶解度,肽T闪点,肽T结构式,肽T购买,肽T熔点,

产品说明	肽T(Peptide T,106362-32-7)是源自HIV-1 gp120的V2区的八肽
Introduction	肽T(Peptide T,106362-32-7) is an octapeptide from the V2 region of HIV gp120. Peptide T is a ligand for theCD4receptor and prevents binding of HIVto the CD4 receptor.
Application1	Peptide T是源自HIV-1 gp120的V2区的八肽。 Peptide T是 CD4 受体的配体，可阻止 HIV 与CD4受体结合。
Application2
Application3

肽T(Peptide T,106362-32-7)药理学：

肽T是一种HIV进入抑制剂，它通过阻断趋化因子5受体（CCR5）发挥作用，目前正在临床试验中，用于治疗HIV相关的神经和体质症状。

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

1.Ruff MR, et al. Peptide T[4-8] is core HIV envelope sequence required for CD4 receptor attachment. Lancet. 1987 Sep 26;2(8561):751.

2.Ruff MR, et al. Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res. 2001 Oct;52(1):63-75.

3.Raychaudhuri SP, et al. Immunomodulatory effects of peptide T on Th 1/Th 2 cytokines. Int J Immunopharmacol. 1999 Sep;21(9):609-15.

4.Sáez-Torres I, et al. Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats. Clin Exp Immunol. 2000 Jul;121(1):151-6.

5Syntheses of mucin-type O-glycopeptides and oligosaccharides using transglycosylation and reverse-hydrolysis activities of Bifidobacterium endo-α-N-acetylgalactosaminidase Glycoconjugate Journal 2009

肽T(Peptide T,106362-32-7)参考文献：

1.Phosphoenolpyruvate-dependent phosphotransferase system of Staphylococcus aureus: factor IIIlac, a trimeric phospho-carrier protein that also acts as a phase transfer catalyst.
Deutscher J;Beyreuther K;Sobek HM;Stüber K;Hengstenberg W Biochemistry. 1982 Sep 28;21(20):4867-73.

Factor IIIlac (FIII) consists of three identical subunits. It could be shown that each of the subunits carries a phosphoryl group upon phosphorylation (P-FIII) with phosphoenolpyruvate (PEP), enzyme I, and histidine-containing phospho-carrier protein (HPr). The phosphoryl group is bound to a histidyl residue in P-FIII. Each subunit of FIII contains four histidyl residues. After tryptic cleavage a peptide was isolated that contained one other histidyl residue besides the active center histidine. By further cleavage of the peptide T-2 with V-8 Staphylococcus aureus protease it could be shown that His-19 in the sequence of the peptide T-2 is the active center histidine. Another peptide (1-38), caused by incomplete tryptic cleavage, could be isolated. It inhibited the phospho-transfer reaction from PEP to the sugar molecule at the step of factor III-enzyme II recognition. It competes with factor III for the binding site of enzyme II, the membrane component. It is a very hydrophobic peptide. This hydrophobic region is buried in factor III. But upon phosphorylation of factor III it is turned out. Thus P-FIII binds to Triton X-100 micelles whereas factor III does not. This conformational change caused by phosphorylation could be shown by proton nuclear magnetic resonance methods [Kalbitzer, H.

2.Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment.
Heseltine PN;Goodkin K;Atkinson JH;Vitiello B;Rochon J;Heaton RK;Eaton EM;Wilkie FL;Sobel E;Brown SJ;Feaster D;Schneider L;Goldschmidts WL;Stover ES Arch Neurol. 1998 Jan;55(1):41-51.

BACKGROUND: ;Cognitive impairment is a common consequence of human immunodeficiency virus (HIV) infection, and dementia is one of the diseases that defines the acquired immunodeficiency syndrome. Peptide T (d-ala-peptide-T-amide) has been reported to block the binding of gp120 to brain tissue and to protect neurons from the toxic effects of gp120 in vitro. In pilot studies, administration of peptide T to HIV-positive patients with cognitive impairment was associated with improvement in cognition and constitutional symptoms.;OBJECTIVE: ;To determine whether the intranasal administration of peptide T would improve cognitive function of HIV-positive patients with cognitive impairment.;PATIENTS AND METHODS: ;This was a 3-site, double-blind, placebo-controlled trial of peptide T given intranasally at a dosage of 2 mg 3 times a day for 6 months. Participants were HIV-seropositive persons with evidence of cognitive deficits on a screening test battery. Concomitant antiretroviral therapy was allowed. Randomization to the 2 study arms was balanced according to several stratification variables, such as CD4+ cell count, severity of cognitive impairment, and antiretroviral therapy at study entry.

3.A 500 MHz study of peptide T in a DMSO solution.
Picone D;Temussi PA;Marastoni M;Tomatis R;Motta A FEBS Lett. 1988 Apr 11;231(1):159-63.

Peptide T, an octapeptide of sequence ASTTTNYT that binds to human T cells, was studied as a zwitterion in DMSOd6 solution by means of proton NMR spectroscopy at 500 MHz. The unusual dispersion of the resonances of residues of the same type (T) makes it possible to assign all resonances to specific residues by means of several 2D techniques. The non-random nature of the conformation is substantiated by the observation of sequential nuclear Overhauser enhancements (NOEs). The low value of the temperature coefficient of the chemical shift of the NH of T8 and a diagnostic NOE between the NHs of T7 and T8 hint that a beta-turn including T5, N6, Y7 and T8 is a prominent conformational feature in solution. The ring current high field shifts of the methyl group and of the NH of T8 are consistent with an interaction with the side-chain of Y7, favoured by the beta-turn.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开